Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease.

PMID: 29178139
Journal: GLIA
Year: 2018
Reference: Glia. 2018 Mar;66(3):637-653. doi: 10.1002/glia.23270. Epub 2017 Nov 27.
Impact factor:
Publication type: Paper in international publication
Authors: Comella, Joan X; Davila, Jose C; Fernandez-Valenzuela, Juan Jose; Galea, Elena; Gomez-Arboledas, Angela; Gutierrez, Antonia; Navarro, Victoria; Nunez-Diaz, Cristina; Sanchez-Mejias, Elisabeth; Sanchez-Mico, Maria Virtudes et al.
DOI: 10.1002/glia.23270

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

PMID: 30018749
Journal: Oncotarget
Year: 2018
Reference: Oncotarget. 2018 Jun 26;9(49):29238-29258. doi: 10.18632/oncotarget.25579. eCollection 2018 Jun 26.
Impact factor: 0
Publication type: Review in national publication
Authors: Cullell, Natalia, Carrera, Caty, Muino, Elena, Torres, Nuria, Krupinski, Jerzy, Fernandez-Cadenas, Israel et al.
DOI: 10.18632/oncotarget.25579

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

PMID: 30018749
Journal: Oncotarget
Year: 2018
Reference: Oncotarget. 2018 Jun 26;9(49):29238-29258. doi: 10.18632/oncotarget.25579. eCollection 2018 Jun 26.
Impact factor:
Publication type: Review in national publication
Authors: Carrera, Caty; Cullell, Natalia; Fernandez-Cadenas, Israel; Krupinski, Jerzy; Muino, Elena; Torres, Nuria et al.
DOI: 10.18632/oncotarget.25579

PHARMACOKINETIC STUDY OF CONVERSION BETWEEN TWO FORMULATIONS OF ONCE-DAILY EXTENDED-RELEASE TACROLIMUS IN STABLE LUNG TRANSPLANT PATIENTS.

PMID: 29965950
Journal: TRANSPLANTATION
Year: 2018
Reference: Transplantation. 2018 Oct;102(10):e439-e446. doi: 10.1097/TP.0000000000002348.
Impact factor: 3.96
Publication type: Paper in international publication
Authors: Roman, Antonio, Vima, Jaume, Sintes, Helena, Saez-Gimenez, Berta, Berastegui, Cristina, Lopez-Meseguer, Manuel, Monforte, Victor, Bravo, Carlos, Gomez-Olles, Susana et al.
DOI: 10.1097/TP.0000000000002348

PHARMACOKINETIC STUDY OF CONVERSION BETWEEN TWO FORMULATIONS OF ONCE-DAILY EXTENDED-RELEASE TACROLIMUS IN STABLE LUNG TRANSPLANT PATIENTS.

PMID: 29965950
Journal: TRANSPLANTATION
Year: 2018
Reference: Transplantation. 2018 Oct;102(10):e439-e446. doi: 10.1097/TP.0000000000002348.
Impact factor:
Publication type: Paper in international publication
Authors: Berastegui, Cristina; Bravo, Carlos; Gomez-Olles, Susana; Lopez-Meseguer, Manuel; Monforte, Victor; Roman, Antonio; Saez-Gimenez, Berta; Sintes, Helena; Vima, Jaume et al.
DOI: 10.1097/TP.0000000000002348

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

PMID: 29237008
Journal: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Year: 2018
Reference: J Antimicrob Chemother. 2018 Mar 1;73(3):732-737. doi: 10.1093/jac/dkx459.
Impact factor: 5.071
Publication type: Paper in international publication
Authors: Khoo, Saye, Molto, Jose, Curran, Adrian, Miranda, Cristina, Challenger, Elizabeth, Santos, Jose Ramon, Ribera, Esteban, Clotet, Bonaventura, Valle, Marta et al.
DOI: 10.1093/jac/dkx459

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

PMID: 29237008
Journal: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Year: 2018
Reference: J Antimicrob Chemother. 2018 Mar 1;73(3):732-737. doi: 10.1093/jac/dkx459.
Impact factor:
Publication type: Paper in international publication
Authors: Challenger, Elizabeth; Clotet, Bonaventura; Curran, Adrian; Khoo, Saye; Miranda, Cristina; Molto, Jose; Ribera, Esteban; Santos, Jose Ramon; Valle, Marta et al.
DOI: 10.1093/jac/dkx459

Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study.

PMID: 29185897
Journal: SUBSTANCE USE & MISUSE
Year: 2018
Reference: Subst Use Misuse. 2018 Jul 3;53(8):1267-1274. doi: 10.1080/10826084.2017.1402056. Epub 2017 Nov 29.
Impact factor: 1.132
Publication type: Paper in international publication
Authors: Grau-Lopez, L, Grau-Lopez, L, Daigre, C, Palma-Alvarez, R F, Rodriguez-Cintas, L, Ros-Cucurull, E, Roncero, C et al.
DOI: 10.1080/10826084.2017.1402056

Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study.

PMID: 29185897
Journal: SUBSTANCE USE & MISUSE
Year: 2018
Reference: Subst Use Misuse. 2018 Jul 3;53(8):1267-1274. doi: 10.1080/10826084.2017.1402056. Epub 2017 Nov 29.
Impact factor:
Publication type: Paper in international publication
Authors: Daigre, C; Grau-Lopez, L; Grau-Lopez, L; Palma-Alvarez, R F; Palma-Alvarez, R F; Rodriguez-Cintas, L; Roncero, C; Ros-Cucurull, E et al.
DOI: 10.1080/10826084.2017.1402056

Pharmacology of Symtuza((R)) (DRV/c/FTC/TAF).

PMID: 30545466
Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Year: 2018
Reference: Enferm Infecc Microbiol Clin. 2018 Dec;36 Suppl 2:10-16. doi: 10.1016/S0213-005X(18)30392-6.
Impact factor: 1.707
Publication type: Paper in national publication
Authors: Curran, Adrian, Navarro, Jordi et al.
DOI: 10.1016/S0213-005X(18)30392-6

Pharmacology of Symtuza((R)) (DRV/c/FTC/TAF).

PMID: 30545466
Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Year: 2018
Reference: Enferm Infecc Microbiol Clin. 2018 Dec;36 Suppl 2:10-16. doi: 10.1016/S0213-005X(18)30392-6.
Impact factor:
Publication type: Paper in national publication
Authors: Curran, Adrian; Navarro, Jordi et al.
DOI: 10.1016/S0213-005X(18)30392-6

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

PMID: 29882016
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2018
Reference: Cancer Chemother Pharmacol. 2018 Aug;82(2):285-298. doi: 10.1007/s00280-018-3610-z. Epub 2018 Jun 7.
Impact factor: 2.808
Publication type: Paper in international publication
Authors: Krop, Ian E, Rodon, Jordi, Perez-Fidalgo, Alejandro, Britten, Carolyn D, Becerra, Carlos, Schellens, Jan, Richards, Donald A, Schuler, Martin, Abu-Khalaf, Maysa, Johnson, Faye M et al.
DOI: 10.1007/s00280-018-3610-z

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

PMID: 29882016
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2018
Reference: Cancer Chemother Pharmacol. 2018 Aug;82(2):285-298. doi: 10.1007/s00280-018-3610-z. Epub 2018 Jun 7.
Impact factor:
Publication type: Paper in international publication
Authors: Abu-Khalaf, Maysa; Baselga, Jose; Becerra, Carlos; Britten, Carolyn D; Burris, Howard; Demanse, David; Duval, Vincent; Edenfield, Jeff; Guerrero-Zotano, Angel; Hackl, Wolfgang et al.
DOI: 10.1007/s00280-018-3610-z

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

PMID: 29247830
Journal: Journal of Thoracic Oncology
Year: 2018
Reference: J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.
Impact factor: 10.336
Publication type: Paper in international publication
Authors: Garon, Edward B, Akimov, Mikhail, Felip, Enriqueta, Barlesi, Fabrice, Besse, Benjamin, Chu, Quincy, Gandhi, Leena, Carcereny, Enric, Sequist, Lecia V, Brunsvig, Paal et al.
DOI: 10.1016/j.jtho.2017.11.131

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

PMID: 29247830
Journal: Journal of Thoracic Oncology
Year: 2018
Reference: J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.
Impact factor:
Publication type: Paper in international publication
Authors: Akimov, Mikhail; Avsar, Emin; Barlesi, Fabrice; Besse, Benjamin; Brunsvig, Paal; Carcereny, Enric; Chouaid, Christos; Chu, Quincy; Felip, Enriqueta; Gandhi, Leena et al.
DOI: 10.1016/j.jtho.2017.11.131

Phase 3, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

PMID: 30052729
Journal: ANNALS OF ONCOLOGY
Year: 2018
Reference: Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.
Impact factor: 13.926
Publication type: Clinical Trials
Authors: Lee, K-W, Wyrwicz, L, Schenker, M, Alsina, M, Ryu, M-H, Chung, H-C, Evesque, L, Al-Batran, S-E, Park, S H, Lichinitser, M et al.
DOI: 10.1093/annonc/mdy264

Phase 3, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

PMID: 30052729
Journal: ANNALS OF ONCOLOGY
Year: 2018
Reference: Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.
Impact factor:
Publication type: Clinical Trials
Authors: Al-Batran, S-E; Alsina, M; Bang, Y-J; Boku, N; Chung, H-C; Conti, I; Evesque, L; Hallwachs, R; Hong, J; Lee, K-W et al.
DOI: 10.1093/annonc/mdy264

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

PMID: 29936064
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2018
Reference: Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.
Impact factor: 7.191
Publication type: Clinical Trials
Authors: Moreno, Lucas, Casanova, Michela, Chisholm, Julia C, Berlanga, Pablo, Chastagner, Pascal B, Baruchel, Sylvain, Amoroso, Loredana, Melcon, Soledad Gallego, Gerber, Nicolas U, Bisogno, Gianni et al.
DOI: 10.1016/j.ejca.2018.05.002

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

PMID: 29936064
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2018
Reference: Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.
Impact factor:
Publication type: Clinical Trials
Authors: Aerts, Isabelle; Amoroso, Loredana; Baruchel, Sylvain; Bergeron, Christophe; Berlanga, Pablo; Bisogno, Gianni; Casanova, Michela; Chastagner, Pascal B; Chen, Nianhang; Chisholm, Julia C et al.
DOI: 10.1016/j.ejca.2018.05.002

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

PMID: 29593099
Journal: ONCOLOGIST
Year: 2018
Reference: Oncologist. 2018 Apr;23(4):401-e38. doi: 10.1634/theoncologist.2017-0691. Epub 2018 Mar 28.
Impact factor: 5.306
Publication type: Paper in international publication
Authors: Edelman, Gerald, Lager, Joanne, Castell, Christelle, Jiang, Jason, Van Allen, Eliezer M, Wagle, Nikhil, Lindeman, Neal I, Sholl, Lynette M, Shapiro, Geoffrey I, Rodon, Jordi et al.
DOI: 10.1634/theoncologist.2017-0691

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

PMID: 29593099
Journal: ONCOLOGIST
Year: 2018
Reference: Oncologist. 2018 Apr;23(4):401-e38. doi: 10.1634/theoncologist.2017-0691. Epub 2018 Mar 28.
Impact factor:
Publication type: Paper in international publication
Authors: Castell, Christelle; Edelman, Gerald; Jiang, Jason; Lager, Joanne; Lindeman, Neal I; Rodon, Jordi; Shapiro, Geoffrey I; Sholl, Lynette M; Van Allen, Eliezer M; Wagle, Nikhil et al.
DOI: 10.1634/theoncologist.2017-0691

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

PMID: 29349598
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2018
Reference: Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.
Impact factor: 3.502
Publication type: Paper in international publication
Authors: Gonzalez, Iria, Lopez-Martin, Jose, Welt, Anja, Levy, Christelle, Joly, Florence, Michielin, Francesca, Jacob, Wolfgang, Adessi, Celine, Moisan, Annie, Meneses-Lorente, Georgina et al.
DOI: 10.1007/s10637-018-0562-4

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

PMID: 29349598
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2018
Reference: Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.
Impact factor:
Publication type: Paper in international publication
Authors: Adessi, Celine; Albanell, Joan; Cejalvo, Juan Miguel; Ceppi, Maurizio; Cervantes, Andres; Cortes, Javier; Dieras, Veronique; Gonzalez, Iria; Hasmann, Max; Jacob, Wolfgang et al.
DOI: 10.1007/s10637-018-0562-4

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

PMID: 30156984
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2018
Reference: J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29.
Impact factor: 26.303
Publication type: Paper in international publication
Authors: Ahn, Myung-Ju, Vansteenkiste, Johan F, Su, Wu-Chou, Felip, Enriqueta, Chia, Vincent, Glaser, Sabine, Pultar, Philippe, Zhao, Sylvia, Peng, Bin, Akimov, Mikhail et al.
DOI: 10.1200/JCO.2018.77.7326

Publications

Publications searcher

Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease.

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

PHARMACOKINETIC STUDY OF CONVERSION BETWEEN TWO FORMULATIONS OF ONCE-DAILY EXTENDED-RELEASE TACROLIMUS IN STABLE LUNG TRANSPLANT PATIENTS.

PHARMACOKINETIC STUDY OF CONVERSION BETWEEN TWO FORMULATIONS OF ONCE-DAILY EXTENDED-RELEASE TACROLIMUS IN STABLE LUNG TRANSPLANT PATIENTS.

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study.

Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study.

Pharmacology of Symtuza((R)) (DRV/c/FTC/TAF).

Pharmacology of Symtuza((R)) (DRV/c/FTC/TAF).

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Phase 3, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

Phase 3, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

Patronage:

Collaborating:

Accreditations: